Risk of Reactivation of Hepatitis B in Hepatitis B Surface Antigen-Negative and Hepatitis B Core Antigen Antibody Positive Patients Receiving Biologic Therapy.
作者信息
Gök Sargın Zeynep
机构信息
Department of Gastroenterology and Hepatology, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey.
出版信息
Turk J Gastroenterol. 2023 Mar;34(3):308-309. doi: 10.5152/tjg.2023.23070.
Abstract
摘要
相似文献
1
Risk of Reactivation of Hepatitis B in Hepatitis B Surface Antigen-Negative and Hepatitis B Core Antigen Antibody Positive Patients Receiving Biologic Therapy.接受生物治疗的乙肝表面抗原阴性和乙肝核心抗原抗体阳性患者中乙肝再激活的风险
Turk J Gastroenterol. 2023 Mar;34(3):308-309. doi: 10.5152/tjg.2023.23070.
2
Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B.生物疗法在乙型肝炎表面抗原阴性期乙型肝炎中复发的风险非常低。
Turk J Gastroenterol. 2023 Feb;34(2):156-160. doi: 10.5152/tjg.2022.22196.
3
Surveillance and treatment protocols to detect and treat hepatitis B virus reactivation in hepatitis B surface antigen-negative/antibody to hepatitis B core antigen-positive patients receiving chemotherapy for onco-hematologic malignancies.用于检测和治疗接受肿瘤血液系统恶性肿瘤化疗的乙肝表面抗原阴性/乙肝核心抗体阳性患者中乙肝病毒再激活的监测和治疗方案。
J Clin Oncol. 2011 Mar 10;29(8):e210; author reply e211. doi: 10.1200/JCO.2010.33.6016. Epub 2011 Jan 10.
4
Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?乙型肝炎病毒再激活：问题是什么，应如何管理？
Clin Liver Dis. 2020 Aug;24(3):317-333. doi: 10.1016/j.cld.2020.04.002. Epub 2020 May 26.
5
The difficulties of managing severe hepatitis B virus reactivation.管理乙型肝炎病毒再激活的困难。
Liver Int. 2011 Jan;31 Suppl 1:104-10. doi: 10.1111/j.1478-3231.2010.02396.x.
6
The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.抗-HBs在慢性丙型肝炎直接抗病毒治疗期间乙肝再激活中的作用
Antivir Ther. 2018;23(6):539-542. doi: 10.3851/IMP3259.
7
Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis.乙肝表面抗原阴性/乙肝核心抗体阳性患者的乙肝病毒再激活风险及常规抗病毒预防的作用
J Clin Oncol. 2009 May 20;27(15):2570-1; author reply 2571-2. doi: 10.1200/JCO.2009.21.9352. Epub 2009 Apr 13.
8
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.乙型肝炎病毒核心抗体的定量检测有助于预测淋巴瘤和乙型肝炎病毒感染已清除患者的乙型肝炎病毒再激活。
J Hepatol. 2018 Aug;69(2):286-292. doi: 10.1016/j.jhep.2018.02.033. Epub 2018 Mar 16.
9
Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.在乙型肝炎或丙型肝炎感染的真实世界环境中，用司库奇尤单抗治疗银屑病的患者中肝炎病毒再激活。
Clin Drug Investig. 2022 Jun;42(6):525-531. doi: 10.1007/s40261-022-01163-5. Epub 2022 May 28.
10
Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.一名非霍奇金淋巴瘤患者在接受化疗前乙肝表面抗原阴性且核心抗体阳性，出现致命性乙肝病毒再激活。
J Clin Gastroenterol. 2009 May-Jun;43(5):496-8. doi: 10.1097/MCG.0b013e3181945942.
引用本文的文献
1
Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy.银屑病管理中的感染风险与疫苗接种：生物治疗的考量
Psoriasis (Auckl). 2025 Apr 11;15:127-144. doi: 10.2147/PTT.S510141. eCollection 2025.
本文引用的文献
1
Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B.生物疗法在乙型肝炎表面抗原阴性期乙型肝炎中复发的风险非常低。
Turk J Gastroenterol. 2023 Feb;34(2):156-160. doi: 10.5152/tjg.2022.22196.
2
Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance.隐匿性乙型肝炎感染与肝细胞癌：流行病学、病毒学、肝癌发生机制及临床意义。
J Hepatol. 2020 Oct;73(4):952-964. doi: 10.1016/j.jhep.2020.05.042. Epub 2020 Jun 3.
3
Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.慢性乙型肝炎的预防、诊断及治疗最新进展：美国肝病研究学会2018年乙型肝炎指南
Clin Liver Dis (Hoboken). 2018 Aug 22;12(1):33-34. doi: 10.1002/cld.728. eCollection 2018 Jul.
4
Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.免疫抑制治疗与乙型肝炎再激活风险：共识报告
Turk J Gastroenterol. 2018 May;29(3):259-269. doi: 10.5152/tjg.2018.18263.
5
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.EASL 2017 临床实践指南：乙型肝炎病毒感染管理。
J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
Zotero 插件